Literature DB >> 22349478

Microbial diagnostics in patients with presumed severe infection in the emergency department.

S Hettwer1, J Wilhelm, M Schürmann, H Ebelt, D Hammer, M Amoury, F Hofmann, A Oehme, D Wilhelms, A S Kekulé, T Klöss, K Werdan.   

Abstract

INTRODUCTION: Sepsis in the early stage is a common disease in emergency medicine, and rapid diagnosis is essential. Our aim was to compare pathogen diagnosis using blood cultures (BC) and the multiplex polymerase chain reaction (PCR) test.Methods. At total of 211 patients admitted to the multidisciplinary emergency department of our university hospital between 2006 and 2009 with suspected severe infection from any origin were studied. Blood samples for BC (aerobic and anaerobic) and multiplex PCR were taken for identification of infectious microorganisms immediately after hospital admission. Results of the BC and PCR correlated with procalcitonin concentration (PCT) and clinical diagnosis of sepsis (≥2 positive SIRS criteria) as well as with severity of disease at admission and with clinical outcome measures.
RESULTS: Results of the BC were available in 200 patients (94.8%) and PCR were available in 119 patients (56.3%), respectively. In total, 87 BC (43.5%) were positive and identified 94 pathogens. In 45 positive PCRs, 47 pathogens (37.8%) were found. Identical results were obtained in 81.4%. In addition, BC identified 9 Gram-positive and 3 Gram-negative bacteria, while PCR added 5 Gram-negative pathogens. Coagulase-negative staphylococci were detected in blood cultures only (n=20, 21.3%), whereas PCR identified significantly more Gram-negative bacteria than BC. In patients with positive PCR results, the PCT level was significantly higher than in patients with negative PCR (15.0±23.3 vs. 8.8±32.8 ng/ml, p<0.001). This difference was not observed for BC (10.6±25.7 vs. 11.6±44.9 ng/ml, p=0.075). The APACHE II score correlated with PCR (19.2±9.1 vs. 15.8±8.9, p<0.05) and was also higher in positive BC (18.7±8.7 vs. 14.4±8.0, p<0.01). Positive PCR and BC were correlated with negative clinical outcomes (e.g., transfer to ICU, mechanical ventilation, renal replacement therapy, death).
CONCLUSION: In patients admitted with suspected severe infection, a high percentage of positive BC and PCR were observed. Positive findings in the PCR correlate with elevated levels of PCT and high APACHE II scores.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349478     DOI: 10.1007/s00063-011-0051-4

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  34 in total

Review 1.  Blood cultures: clinical aspects and controversies.

Authors:  J M Mylotte; A Tayara
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-03       Impact factor: 3.267

2.  The emerging power of molecular diagnostics: towards improved management of life-threatening infection.

Authors:  M J Struelens; R de Mendonça
Journal:  Intensive Care Med       Date:  2001-10-30       Impact factor: 17.440

3.  Evaluation of the LightCycler SeptiFast test in the rapid etiologic diagnostic of infectious endocarditis.

Authors:  J P Casalta; F Gouriet; V Roux; F Thuny; G Habib; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-12-02       Impact factor: 3.267

4.  Serum procalcitonin in diagnosis of bacteremia.

Authors:  Ubonvan Jongwutiwes; Klairung Suitharak; Surapee Tiengrim; Visanu Thamlikitkul
Journal:  J Med Assoc Thai       Date:  2009-03

5.  CKD and risk of hospitalization and death with pneumonia.

Authors:  Matthew T James; Hude Quan; Marcello Tonelli; Braden J Manns; Peter Faris; Kevin B Laupland; Brenda R Hemmelgarn
Journal:  Am J Kidney Dis       Date:  2009-05-17       Impact factor: 8.860

6.  Diagnostic techniques in bloodstream infections: where are we going?

Authors:  Stefania Stefani
Journal:  Int J Antimicrob Agents       Date:  2009       Impact factor: 5.283

Review 7.  Rapid methods for diagnosis of bloodstream infections.

Authors:  Mariam Klouche; Uwe Schröder
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

8.  Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery.

Authors:  Julien Amour; Aurélie Birenbaum; Olivier Langeron; Yannick Le Manach; Michèle Bertrand; Pierre Coriat; Bruno Riou; Maguy Bernard; Pierre Hausfater
Journal:  Crit Care Med       Date:  2008-04       Impact factor: 7.598

9.  Epidemiology of severe sepsis in the emergency department and difficulties in the initial assistance.

Authors:  Ederlon Rezende; João Manoel Silva; Alexandre Marine Isola; Edvaldo Vieira Campos; Cristina Prata Amendola; Samantha Longhi Almeida
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

10.  Impact of previous sepsis on the accuracy of procalcitonin for the early diagnosis of blood stream infection in critically ill patients.

Authors:  Pierre Emmanuel Charles; Sylvain Ladoire; Aurélie Snauwaert; Sébastien Prin; Serge Aho; André Pechinot; Niels-Olivier Olsson; Bernard Blettery; Jean-Marc Doise; Jean-Pierre Quenot
Journal:  BMC Infect Dis       Date:  2008-12-02       Impact factor: 3.090

View more
  9 in total

Review 1.  Accuracy of LightCycler(®) SeptiFast for the detection and identification of pathogens in the blood of patients with suspected sepsis: a systematic review and meta-analysis.

Authors:  Paul Dark; Bronagh Blackwood; Simon Gates; Danny McAuley; Gavin D Perkins; Ronan McMullan; Claire Wilson; Daniel Graham; Kate Timms; Geoffrey Warhurst
Journal:  Intensive Care Med       Date:  2014-11-22       Impact factor: 17.440

2.  Molecular diagnosis of sepsis: New aspects and recent developments.

Authors:  O Liesenfeld; L Lehman; K-P Hunfeld; G Kost
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-03-14

3.  Diagnostic accuracy of SeptiFast multi-pathogen real-time PCR in the setting of suspected healthcare-associated bloodstream infection.

Authors:  Geoffrey Warhurst; Satanayarana Maddi; Graham Dunn; Murad Ghrew; Paul Chadwick; Peter Alexander; Andrew Bentley; John Moore; Michael Sharman; Gordon L Carlson; Duncan Young; Paul Dark
Journal:  Intensive Care Med       Date:  2014-11-19       Impact factor: 17.440

Review 4.  Emerging Technologies for Molecular Diagnosis of Sepsis.

Authors:  Mridu Sinha; Julietta Jupe; Hannah Mack; Todd P Coleman; Shelley M Lawrence; Stephanie I Fraley
Journal:  Clin Microbiol Rev       Date:  2018-02-28       Impact factor: 26.132

5.  Outcome prediction using clinical scores and biomarkers in patients with presumed severe infection in the emergency department.

Authors:  J Wilhelm; S Hettwer; D Hammer; M Schürmann; A Christoph; M Amoury; T Klöss; R Finke; H Ebelt; K Werdan
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-08-10       Impact factor: 0.840

6.  [Indocyanine green elimination for the evaluation of liver function: prognostic value in patients with community-acquired sepsis].

Authors:  S A Kaulen; C Hübner; J Mieth; K Spindler; R Schwab; R Wimmer; J Wilhelm; M Amoury; M Girndt; K Werdan; H Ebelt
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-09-03       Impact factor: 0.840

7.  APACHE II scoring to predict outcome in post-cardiac arrest.

Authors:  Michael W Donnino; Justin D Salciccioli; Andre Dejam; Tyler Giberson; Brandon Giberson; Cristal Cristia; Shiva Gautam; Michael N Cocchi
Journal:  Resuscitation       Date:  2012-11-20       Impact factor: 5.262

8.  Comparison of three different commercial PCR assays for the detection of pathogens in critically ill sepsis patients.

Authors:  J Schreiber; A Nierhaus; S A Braune; G de Heer; S Kluge
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-03-22       Impact factor: 0.840

Review 9.  Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis.

Authors:  Shy-Shin Chang; Wen-Han Hsieh; Ting-Shou Liu; Si-Huei Lee; Chih-Hung Wang; Hao-Chang Chou; Yee Hui Yeo; Ching-Ping Tseng; Chien-Chang Lee
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.